GSK Sees One Downside To Size: Co-Promotion Deals Can Be Thorny
Executive Summary
The outcome of GlaxoSmithKline's negotiations for the rights to Boehringer Ingelheim's respiratory drug Spiriva illustrates one difficulty for GSK in pursuing licensing agreements to fill out its pipeline.